Drugs / MH004
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04815148 | Apr 2021 → Mar 2022 | atopic eczema, rheumatoid arthritis | Minghui Pharmaceutical Pty Ltd | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07182864 | Jan → Sep 2022 | atopic eczema | Minghui Pharmaceutical (Hangzhou) Ltd | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07682506 | Jul 2026 → Feb 2028 expected | vitiligo | Minghui Pharmaceutical (Hangzhou) Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07185282 | Jun 2023 → Dec 2024 | atopic eczema | Minghui Pharmaceutical (Hangzhou) Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MH004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07682506 ↗ |
| Route | Topical | “Spread approx. 1 g of MH004 topical cream to the upper thigh skin.” NCT04815148 ↗ |